<DOC>
	<DOCNO>NCT00389935</DOCNO>
	<brief_summary>The purpose study determine whether Thalidomide effective treatment arteriovenous malformation gastrointestinal tract .</brief_summary>
	<brief_title>Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding</brief_title>
	<detailed_description>Arteriovenous malformation ( AVM 's ) commonest vascular abnormality gut . AVM 's Angiodysplasia may acquire inherited hereditary hemorrhagic telangiectasia ( HHT ) . Repeated episode gastrointestinal bleeding ( GIB ) , especially elderly attribute angiodysplasia . Clinically significant GIB may also see 40 % HHT patient , usually fourth fifth decade life . GIB may manifest acute major hemorrhage , slow intermittent blood loss combination finding patient may symptomless , present acute bleed iron deficiency anemia . Recurrent hemorrhage persistent iron-deficiency anemia common despite supplemental iron therapy patient require repeated transfusion . Amongst patient preexist co-morbidities , repeat bleeding may lead significant morbidity mortality . Furthermore , re-bleeding among patient consumes disproportionate share healthcare resource devote multiple admission , repeat endoscopy blood transfusion . There effective treatment option available currently . The purpose study determine whether Thalidomide effective treatment arteriovenous malformation gastrointestinal tract .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Arteriovenous Malformations</mesh_term>
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Telangiectasia , Hereditary Hemorrhagic</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients must 18 year age old Patient must great 2 episode overt bleed last 2 year require &gt; 4 unit PRBC bleed 20 AVM . AVM 's identified optical/capsule endoscopy angiography . Patients must adequate hematologic , renal liver function ( i.e . Platelets ≥ 100,000/mm3 , Creatinine ≤ 1.7mg/dl , Total Bilirubin ≤ 2.5mg/dl , Transaminases ≤ 4 time upper limit institutional norm ) Patients must able provide write informed consent . Patients potential pregnancy impregnate partner must agree follow acceptable birth control method ( describe detail thalidomide drug information section ) avoid conception . Women childbearing potential must negative pregnancy test prior treatment protocol . Men take thalidomide must agree use latex condom every time sex woman since show thalidomide find semen . All patient must agree participate S.T.E.P.S.® program ( System Thalidomide Education Prescribing Safety ) . All patient must educate requirement S.T.E.P.S.® program . Patients require complete S.T.E.P.S.® survey sign additional consent form indicate understand information provide part S.T.E.P.S.® educational counseling . Estimated life expectancy must great 2 month . Pregnant and/ lactate female Personal history thromboembolic disease History seizure activity History neoplasm except basal cell carcinoma insitu History severe neuropathy Women child bear potential Inability comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Gastrointestinal Bleeding</keyword>
	<keyword>Arteriovenous Malformation</keyword>
	<keyword>Angiodysplasia</keyword>
	<keyword>Hereditary Hemorrhagic Telangiectasia</keyword>
	<keyword>Obscure Bleeding</keyword>
</DOC>